Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Therapies for Treatment-Resistant Depression
Neuropharmacology and Neurostimulation
- 1st Edition - June 1, 2025
- Editors: James Murrough, Dennis Charney
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 0 5 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 0 6 - 6
Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTherapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.
The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.
- Defines treatment-resistant depression, including epidemiology
- Outlines neuroimaging and brain-based biomarkers in treatment-resistant depression using patient data
- Reviews safety and monitoring protocols of ketamine in clinical care
practicing psychiatrists and other providers in allied mental health fields, researchers and scientists in psychiatry and neuroscience in academic and industry, psychiatry and medical residents and postdoctoral fellows in psychiatry and clinical neuroscience programs, graduate students in biomedical research
1. Introduction
2. Treatment-Resistant Depression: Definitions, Epidemiology and Public Health Burden
3. Overview of Current Pharmacotherapy Options and Treatment Algorithms for TRD
4. From Novel Molecules to New Therapeutics for Mood Disorders: Pathways of Drug Discovery
5. Neuroimaging and Brain Based Biomarkers in Treatment-Resistant Depression
6. Inflammation and Peripheral Biomarkers in Treatment-Resistant Depression
7. Role of the Glutamate System in Treatment-Resistant Depression
8. Role of the GABA System in Treatment-Resistant Depression
9. Role of the Neuropeptides and Other Neuro-active Hormones in Treatment-Resistant Depression
10. Ketamine for Treatment-Resistant Depression: Discovery and Current Directions in Research and Clinical Care
11. Safety and Monitoring of Ketamine in Clinical Care
12. Development and Efficacy of Esketamine Treatment-Resistant Depression
13. Novel Glutamate Modulators in Development for Treatment-Resistant Depression
14. Brexanolone and Other GABA Modulators for Treatment-Resistant Depression
15. Special Topics: Psilocybin and Other Psychedelic Agents in Development for TRD
16. Special Topics: Role of Biomakers in Treatment Selection for Treatment-Resistant Depression
17. Special Topics: Current and Future Role of Genetics and Genomics in Treatment-Resistant Depression
2. Treatment-Resistant Depression: Definitions, Epidemiology and Public Health Burden
3. Overview of Current Pharmacotherapy Options and Treatment Algorithms for TRD
4. From Novel Molecules to New Therapeutics for Mood Disorders: Pathways of Drug Discovery
5. Neuroimaging and Brain Based Biomarkers in Treatment-Resistant Depression
6. Inflammation and Peripheral Biomarkers in Treatment-Resistant Depression
7. Role of the Glutamate System in Treatment-Resistant Depression
8. Role of the GABA System in Treatment-Resistant Depression
9. Role of the Neuropeptides and Other Neuro-active Hormones in Treatment-Resistant Depression
10. Ketamine for Treatment-Resistant Depression: Discovery and Current Directions in Research and Clinical Care
11. Safety and Monitoring of Ketamine in Clinical Care
12. Development and Efficacy of Esketamine Treatment-Resistant Depression
13. Novel Glutamate Modulators in Development for Treatment-Resistant Depression
14. Brexanolone and Other GABA Modulators for Treatment-Resistant Depression
15. Special Topics: Psilocybin and Other Psychedelic Agents in Development for TRD
16. Special Topics: Role of Biomakers in Treatment Selection for Treatment-Resistant Depression
17. Special Topics: Current and Future Role of Genetics and Genomics in Treatment-Resistant Depression
- No. of pages: 425
- Language: English
- Edition: 1
- Published: June 1, 2025
- Imprint: Academic Press
- Paperback ISBN: 9780443160059
- eBook ISBN: 9780443160066
JM
James Murrough
I am Associate Professor with Tenure of Psychiatry and Neuroscience, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action.
Affiliations and expertise
Associate Professor, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USADC
Dennis Charney
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Affiliations and expertise
Biological psychiatrist and researcher, Icahn School of Medicine at Mount Sinai, New York, NY, USA